Dr. McKay Discusses Immunotherapy Trials in RCC

Video

Rana R. McKay, MD, medical oncologist, assistant professor, Moores Cancer Center at the University of California, San Diego, discusses immunotherapy trials in renal cell carcinoma.

Rana R. McKay, MD, medical oncologist, assistant professor, Moores Cancer Center at the University of California, San Diego, discusses immunotherapy trials in renal cell carcinoma (RCC).

Data presented at the 2017 ESMO Congress showed that the combination of nivolumab (Opdivo) plus ipilimumab (Yervoy) improved survival and response rates for patients with intermediate- and poor-risk disease, says McKay.

Currently, there are phase III trials exploring combinations of VEGF and immunotherapy in RCC, such as the combination of cabozantinib (Cabometyx) plus nivolumab with or without ipilimumab, and the combination of axitinib (Inlyta) and pembrolizumab (Keytruda).

Related Videos
Ricardo D. Parrondo, MD, hematologist/oncologist, Mayo Clinic
Ilyas Sahin, MD
Raj Singh, MD
Jaime R. Merchán, MD, professor, co-leader, Translational and Clinical Oncology Research Program, director, Phase 1 Clinical Trials Program, Department of Medicine, Division of Medical Oncology, the University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center
Saad J. Kenderian, MB, CHB
Tycel Phillips, MD
Minesh Mehta, MD
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,